| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PNAS..112.1839L |
| P356 | DOI | 10.1073/PNAS.1424171112 |
| P932 | PMC publication ID | 4330785 |
| P698 | PubMed publication ID | 25605917 |
| P5875 | ResearchGate publication ID | 273352737 |
| P2093 | author name string | Wei Li | |
| Yuan Gao | |||
| Keith Mikule | |||
| Arthur B Pardee | |||
| Youzhi Li | |||
| David Leggett | |||
| Sarah Keates | |||
| Chiang J Li | |||
| Harry A Rogoff | |||
| Sylaja Murikipudi | |||
| P2860 | cites work | Drug Resistance: Challenges to Effective Therapy | Q37864345 |
| The developing cancer stem-cell model: clinical challenges and opportunities | Q37980960 | ||
| Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. | Q38023942 | ||
| Emerging insights into resistance to BRAF inhibitors in melanoma | Q38167587 | ||
| Revisiting STAT3 signalling in cancer: new and unexpected biological functions | Q38262473 | ||
| CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation | Q39512947 | ||
| Targeting of CD44 eradicates human acute myeloid leukemic stem cells | Q40228130 | ||
| Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis | Q42972239 | ||
| TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells | Q45077632 | ||
| A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis | Q24307454 | ||
| Phenotypic characterization of human colorectal cancer stem cells | Q24674126 | ||
| Prospective identification of tumorigenic breast cancer cells | Q24683474 | ||
| Cancer stem cells--important players in tumor therapy resistance | Q26823015 | ||
| Concise Review: The Sox2-Oct4 Connection: Critical Players in a Much Larger Interdependent Network Integrated at Multiple Levels | Q27001663 | ||
| A human colon cancer cell capable of initiating tumour growth in immunodeficient mice | Q27860831 | ||
| Stem cells, cancer, and cancer stem cells | Q27860878 | ||
| Identification of human brain tumour initiating cells | Q27860921 | ||
| A cell initiating human acute myeloid leukaemia after transplantation into SCID mice | Q28131777 | ||
| Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells | Q28250509 | ||
| Identification and expansion of the tumorigenic lung cancer stem cell population | Q28259332 | ||
| Identification of pancreatic cancer stem cells | Q28286997 | ||
| Cancer stem cells in solid tumours: accumulating evidence and unresolved questions | Q28293535 | ||
| Model of tumor dormancy/recurrence after short-term chemotherapy | Q28539003 | ||
| Stat3 as an oncogene | Q29614606 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy | Q29617584 | ||
| Tumour stem cells and drug resistance | Q29617742 | ||
| Tumour heterogeneity and cancer cell plasticity | Q29617990 | ||
| Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells | Q29617991 | ||
| Wnt activity defines colon cancer stem cells and is regulated by the microenvironment | Q29618024 | ||
| Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma | Q29620604 | ||
| A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia | Q33182313 | ||
| ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma | Q33939548 | ||
| The role of STATs in transcriptional control and their impact on cellular function | Q33941346 | ||
| Nonadhesive Culture System as a Model of Rapid Sphere Formation with Cancer Stem Cell Properties | Q34168436 | ||
| Induction of cancer cell stemness by chemotherapy | Q34316857 | ||
| Ionizing radiation induces stemness in cancer cells | Q34395869 | ||
| Transcription factors as targets for cancer therapy | Q34932264 | ||
| The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors | Q35572396 | ||
| Concise Review: Pursuing Self-Renewal and Pluripotency with the Stem Cell Factor Nanog | Q36997249 | ||
| Module map of stem cell genes guides creation of epithelial cancer stem cells | Q37067205 | ||
| Cancer stem cell and cancer stemloids: from biology to therapy | Q37111467 | ||
| Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. | Q37151086 | ||
| Cancer stem cells and tumor response to therapy: current problems and future prospects | Q37403290 | ||
| Treatment resistance in stem cells and breast cancer | Q37406059 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1839-1844 | |
| P577 | publication date | 2015-01-20 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Suppression of cancer relapse and metastasis by inhibiting cancer stemness | |
| P478 | volume | 112 |
| Q61802020 | 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells |
| Q64244208 | A Novel Combination Cancer Therapy with Iron Chelator Targeting Cancer Stem Cells via Suppressing Stemness |
| Q64908014 | A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer. |
| Q41691950 | A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer |
| Q90259957 | A framework for the development of effective anti-metastatic agents |
| Q93054756 | A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells |
| Q90310096 | A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 signaling |
| Q92787908 | A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells |
| Q102063580 | A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors |
| Q37684647 | Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity |
| Q26744536 | Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal |
| Q38971795 | Approaches for targeting cancer stem cells drug resistance |
| Q64269621 | BP‑1‑102 exerts an antitumor effect on the AGS human gastric cancer cell line through modulating the STAT3 and MAPK signaling pathways |
| Q49189846 | Beyond Alkylating Agents for Gliomas: Quo Vadimus? |
| Q89965741 | Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets |
| Q90131783 | Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death |
| Q38511172 | Bioregulation |
| Q91999244 | CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling |
| Q26770274 | Cancer Stem Cell Plasticity Drives Therapeutic Resistance |
| Q50027179 | Cancer Stem Cells, Bone and Tumor Microenvironment: Key Players in Bone Metastases |
| Q46088698 | Cancer recurrence monitoring using hyperpolarized [1-13C]pyruvate metabolic imaging in murine breast cancer model. |
| Q38647014 | Cancer stem cell research in Iran: potentials and challenges. |
| Q38950219 | Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance |
| Q86838788 | Cancer stem cells: Targeting the root of cancer relapse |
| Q47158074 | Carnosol controls the human glioblastoma stemness features through the epithelial-mesenchymal transition modulation and the induction of cancer stem cell apoptosis. |
| Q39038994 | Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety |
| Q38815071 | Chemotherapy for advanced gastric cancer: future perspective in Japan |
| Q45067426 | Classifying the evolutionary and ecological features of neoplasms |
| Q33922534 | Clinical impact of tumour biology in the management of gastroesophageal cancer |
| Q44731136 | Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers |
| Q39112034 | Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells |
| Q28081553 | Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation |
| Q57455148 | Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success |
| Q60929057 | DEAD-box helicase 27 plays a tumor-promoter role by regulating the stem cell-like activity of human colorectal cancer cells |
| Q93204682 | DLG5 suppresses breast cancer stem cell-like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression |
| Q64947408 | Deep Tumor-Penetrated Nanocages Improve Accessibility to Cancer Stem Cells for Photothermal-Chemotherapy of Breast Cancer Metastasis. |
| Q89857370 | Differential sequences and single nucleotide polymorphism of exosomal SOX2 DNA in cancer |
| Q37639772 | Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting |
| Q58577525 | Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells |
| Q37652650 | Effects of U0126 and MK2206 on cell growth and re-growth of endometriotic stromal cells grown on substrates of varying stiffness |
| Q37129279 | Embryonic stem cell preconditioned microenvironment suppresses tumorigenic properties in breast cancer |
| Q55515412 | Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. |
| Q57111080 | Emerging Therapies in the Management of Advanced-Stage Gastric Cancer |
| Q132042456 | Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells |
| Q92282534 | Endoplasmic Reticulum Stress Pathway, the Unfolded Protein Response, Modulates Immune Function in the Tumor Microenvironment to Impact Tumor Progression and Therapeutic Response |
| Q60931354 | Engineered Models of Tumor Dormancy and Reactivation |
| Q87179773 | Epithelial-mesenchymal transition: a new target in anticancer drug discovery |
| Q26801710 | Evolutionary determinants of cancer |
| Q92156808 | Fibronectin in Cancer: Friend or Foe |
| Q36241043 | Functional significance of CD105-positive cells in papillary renal cell carcinoma. |
| Q38717511 | Generation of an inducible mouse model to reversibly silence Stat3. |
| Q91276909 | Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation |
| Q64914568 | Glucosamine decreases the stemness of human ALDH+ breast cancer stem cells by inactivating STAT3. |
| Q47282038 | HIF-1α promotes autophagic proteolysis of Dicer and enhances tumor metastasis. |
| Q60302891 | HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer |
| Q32177089 | Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples |
| Q37708991 | Heparan sulfate hexasaccharide selectively inhibits cancer stem cells self-renewal by activating p38 MAP kinase |
| Q36165598 | Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche |
| Q93018164 | Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane |
| Q47100629 | Hyperhomocysteinemia, Suppressed Immunity, and Altered Oxidative Metabolism Caused by Pathogenic Microbes in Atherosclerosis and Dementia |
| Q92551740 | IL-11 drives postsurgical hepatocellular carcinoma recurrence |
| Q36502358 | Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysis |
| Q30238811 | Identifying and targeting cancer stem cells in the treatment of gastric cancer |
| Q93190592 | If You Cannot Win Them, Join Them: Understanding New Ways to Target STAT3 by Small Molecules |
| Q52616966 | Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells |
| Q49849111 | In vitro and in vivo effects of MK2206 and chloroquine combination therapy on endometriosis: Autophagy may be required for regrowth of endometriosis. |
| Q60913777 | Inhibiting STAT3 in a murine model of human breast cancer-induced bone pain delays the onset of nociception |
| Q57028266 | Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells |
| Q94460537 | LncRNA WT1-AS over-expression inhibits non-small cell lung cancer cell stemness by down-regulating TGF-β1 |
| Q40975462 | Loss of Endometrial Plasticity in Recurrent Pregnancy Loss. |
| Q90266844 | MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma |
| Q57112976 | Mammary Stem Cells and Breast Cancer Stem Cells: Molecular Connections and Clinical Implications |
| Q64061518 | Metabolism-Based Therapeutic Strategies Targeting Cancer Stem Cells |
| Q28076041 | Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer |
| Q36354866 | Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity |
| Q94561568 | Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer |
| Q49351167 | Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial |
| Q91660543 | Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells |
| Q38675856 | Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor |
| Q33734466 | Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro |
| Q38759129 | New agents on the horizon in gastric cancer |
| Q48943023 | New orally active DNA minor groove binding small molecule CT-1 acts against breast cancer by targeting tumor DNA damage leading to p53-dependent apoptosis |
| Q64951391 | Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks. |
| Q64990976 | Next-generation sequencing and biomarkers for gastric cancer: what is the future? |
| Q132047915 | Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review |
| Q38870465 | Novel STAT 3 inhibitors for treating gastric cancer |
| Q37688017 | Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells |
| Q53750080 | Novel pharmaceutical treatment approaches for gastric cancer |
| Q38794338 | Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications |
| Q91785141 | Oncogenic zinc finger protein ZNF322A promotes stem cell-like properties in lung cancer through transcriptional suppression of c-Myc expression |
| Q33902576 | Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling |
| Q48156973 | Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles. |
| Q36998357 | Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling |
| Q39406329 | Overview of Cancer Stem Cells and Stemness for Community Oncologists |
| Q92705174 | Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma |
| Q38682533 | Perspective: Cooperation of Nanog, NF-κΒ, and CXCR4 in a regulatory network for directed migration of cancer stem cells |
| Q99551134 | Pharmacophore hybridisation and nanoscale assembly to discover self-delivering lysosomotropic new-chemical entities for cancer therapy |
| Q38656908 | Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments. |
| Q39039925 | Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer |
| Q39424549 | Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis |
| Q92445524 | Repurposing Antibacterial AM404 as a Potential Anticancer Drug for Targeting Colorectal Cancer Stem-Like Cells |
| Q38633691 | Repurposing itraconazole as an anticancer agent |
| Q39190733 | Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme |
| Q92154668 | STAT3 Activation and Oncogenesis in Lymphoma |
| Q90400267 | STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model |
| Q58778783 | STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer |
| Q39145689 | STAT3 activation in infection and infection-associated cancer |
| Q42324012 | STAT3 and ERK pathways are involved in cell growth stimulation of the ST2/IL1RL1 promoter |
| Q90751298 | STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers |
| Q91211189 | STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells |
| Q89537609 | Self-Renewal Signalling Pathway Inhibitors: Perspectives on Therapeutic Approaches for Cancer Stem Cells |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q64114562 | Single‑cell intratumoral stemness analysis reveals the involvement of cell cycle and DNA damage repair in two different types of esophageal cancer |
| Q40971187 | Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells |
| Q50063665 | Structurally modulated codelivery of siRNA and Argonaute 2 for enhanced RNA interference |
| Q38792113 | Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin |
| Q55015991 | Targeted Therapies for Pancreatic Cancer. |
| Q64249982 | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| Q60956875 | Targeting Cancer Stem Cells to Overcome Chemoresistance |
| Q64885776 | Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer. |
| Q89776510 | Targeting DNA binding proteins for cancer therapy |
| Q49167162 | Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics |
| Q92512238 | Targeting cancer stem cells in drug discovery: Current state and future perspectives |
| Q57805012 | Targeting colon cancer with the novel STAT3 inhibitor bruceantinol |
| Q100750176 | Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer |
| Q92652651 | Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers |
| Q38600094 | Targeting the Wnt signaling pathway in colorectal cancer |
| Q64099576 | The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics |
| Q38645695 | The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. |
| Q97074390 | The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication |
| Q92421507 | The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042 |
| Q38691017 | The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible |
| Q92980181 | The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis |
| Q38691172 | The immune system and cancer evasion strategies: therapeutic concepts |
| Q64110601 | Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies |
| Q26778983 | Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer |
| Q90712078 | Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map |
| Q64260465 | Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells |
| Q99212125 | Transfer of metastatic traits via miR-200c in extracellular vesicles derived from colorectal cancer stem cells is inhibited by atractylenolide I |
| Q88748954 | Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer |
| Q38824383 | Tumor-Initiating Cells: Emerging Biophysical Methods of Isolation |
| Q37649057 | Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies. |
| Q58787017 | Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells |
| Q91587954 | Wnt/β-Catenin Signaling in Liver Cancers |
| Q41281151 | YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells |
Search more.